Analysts expect Cerecor Inc (NASDAQ:CERC) to announce earnings per share (EPS) of ($0.15) for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Cerecor’s earnings. The business is scheduled to issue its next quarterly earnings report on Thursday, February 13th.
According to Zacks, analysts expect that Cerecor will report full-year earnings of ($0.50) per share for the current year, with EPS estimates ranging from ($0.53) to ($0.46). For the next fiscal year, analysts forecast that the company will report earnings of ($0.52) per share, with EPS estimates ranging from ($0.63) to ($0.40). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side analysts that cover Cerecor.
Cerecor (NASDAQ:CERC) last announced its quarterly earnings results on Thursday, November 14th. The company reported ($0.07) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.13) by $0.06. The business had revenue of $5.61 million for the quarter, compared to analysts’ expectations of $5.15 million. Cerecor had a negative net margin of 113.66% and a negative return on equity of 121.32%.
Shares of Cerecor stock traded up $0.08 on Friday, hitting $3.63. The company had a trading volume of 1,288 shares, compared to its average volume of 57,243. Cerecor has a 1 year low of $2.71 and a 1 year high of $7.65. The company has a debt-to-equity ratio of 0.78, a quick ratio of 0.71 and a current ratio of 0.73. The stock has a 50 day moving average of $3.36 and a 200-day moving average of $3.97.
In other Cerecor news, major shareholder Armistice Capital Master Fund bought 2,200,000 shares of the stock in a transaction dated Friday, September 6th. The shares were bought at an average cost of $3.05 per share, for a total transaction of $6,710,000.00. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Armistice Capital, Llc bought 1,000,000 shares of the stock in a transaction dated Friday, September 6th. The shares were acquired at an average price of $2.95 per share, for a total transaction of $2,950,000.00. The disclosure for this purchase can be found here. Company insiders own 64.30% of the company’s stock.
A number of hedge funds and other institutional investors have recently bought and sold shares of CERC. Charles Schwab Investment Management Inc. purchased a new stake in Cerecor in the second quarter worth $288,000. Northern Trust Corp grew its position in Cerecor by 47.4% during the 2nd quarter. Northern Trust Corp now owns 55,971 shares of the company’s stock valued at $304,000 after purchasing an additional 17,999 shares during the last quarter. Bank of New York Mellon Corp grew its position in Cerecor by 294.9% during the 2nd quarter. Bank of New York Mellon Corp now owns 57,428 shares of the company’s stock valued at $312,000 after purchasing an additional 42,885 shares during the last quarter. JPMorgan Chase & Co. increased its stake in Cerecor by 612.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 72,670 shares of the company’s stock valued at $355,000 after purchasing an additional 62,473 shares in the last quarter. Finally, Millennium Management LLC purchased a new position in Cerecor in the third quarter worth about $305,000. Institutional investors and hedge funds own 60.87% of the company’s stock.
Cerecor Inc, a pharmaceutical company, focuses on pediatric health care. Its lead product portfolio includes prescribed dietary supplements, such as Poly-Vi-Flor and Tri-Vi-Flor; and prescription drugs, such as Millipre, Ulesfia, Karbinal ER, AcipHex Sprinkle, and Cefaclor for oral suspension, as well as Flexichamber a medical device.
Further Reading: What is an overbought condition?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cerecor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerecor and related companies with MarketBeat.com's FREE daily email newsletter.